Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
Save to Existing Project
Save to a New Project
Short Lipopeptide Inhibitor for HIV-1
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID:
Sphingolipid-peptide conjugates with potent anti-viral activity....
Contact Galit Mazooz, ph.d.
Email me a copy of this message

Sphingolipid-peptide conjugates with potent anti-viral activity.

According to the WHO, 34 million people around the world are afflicted with HIV, the causative agent of AIDS, with approximately 2.5 million new infections diagnosed each year. The development of new drugs against HIV has been the focus of intense research since its discovery. The market size of HIV-1 treatment is indeed significant with drug sales expected to rise from $13.3 bn in 2011 to $16.7 bn in 2020 in the Western world alone. Nevertheless, there is a highly unmet need for innovative HIV treatment approaches. One such approach is the design of early entry inhibitors that are able to block viral fusion and entry into the host cell. The present technology presents sphingolipid-peptide conjugates (sphingo-peptides) with a potent capacity to interfere with HIV viral fusion.


    • Design of novel HIV therapeutics.

    • Extension of half-life of current HIV fusion inhibitors.

    • Topical blockers of viral transmission.


    • Blocking viral entry prevents all subsequent intracellular steps, most importantly viral genome integration.

    • Sphingolipid conjugates improve efficacy and half-life of current HIV fusion inhibitors.

    • Sphingopeptides were shown to be effective against certain drug-resistant strains.

    • A unique mode of action that reduces the likelihood of developing resistant strains.

Technology's Essence

The first step in the life cycle of enveloped viruses such as the HIV-1 is entry into their host cells by membrane fusion. Therefore, the dynamic process of HIV fusion and entry

represents a valid target for rational drug design. A team of researchers at the Weizmann Institute has developed unique sphingolipid-peptide (short peptides less 17 amino acids) conjugates that block the fusion of the HIV virus to its host cell membrane. Remarkably, the sphingolipid moiety endowed potent anti-viral activity to otherwise poorly and nonactive peptides. The peptide sequence is based on the reserved core of the virus therefore, not likely to accumulate mutations. Moreover, the sphingo-peptide inhibitors were shown to be highly effective against both wt as well as drug-resistant HIV strains.


Last Updated May 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE